COPD and glycopyrronium responsiveness assessment: An appraisal

Clinical Trial Registration: ECR/159/Inst/WB/2013/RR-20 Background: Glycopyrronium bromide (a long-acting antimuscarinic agent: LAMA) appears pharmacokinetically suitable for testing bronchodilator responsiveness as salbutamol (short-acting β2-agonist: SABA). Exploring the feasibility, acceptability...

Full description

Saved in:
Bibliographic Details
Published in:Lung India 2023-05, Vol.40 (3), p.227-234
Main Authors: Bhattacharyya, Parthasarathi, Saha, Dipanjan, Chatterjee, Moumita, Sengupta, Sayoni, Dey, Debkanya, Banerjee, Rajat
Format: Article
Language:English
Subjects:
Albuterol
antimuscarinic agents
bronchodilator reversibility
Bronchodilators
Chronic obstructive pulmonary disease
fev1
glycopyrronium
lama
Lung diseases, Obstructive
Original
saba
salbutamol
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical Trial Registration: ECR/159/Inst/WB/2013/RR-20 Background: Glycopyrronium bromide (a long-acting antimuscarinic agent: LAMA) appears pharmacokinetically suitable for testing bronchodilator responsiveness as salbutamol (short-acting β2-agonist: SABA). Exploring the feasibility, acceptability, degree of reversibility with glycopyrronium, and its comparison with that of salbutamol may be intriguing. Methods: New, consecutive, and willing outpatient attendees in the same season of the two consecutive years with chronic obstructive pulmonary disease (FEV1/FVC
ISSN:0970-2113
0974-598X
DOI:10.4103/lungindia.lungindia_376_22